|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 11,793,766: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 11,793,766?
U.S. Patent 11,793,766 issued on October 10, 2023, covers a novel pharmaceutical composition and its use. The patent primarily claims a specific class of compounds, methods of synthesis, and therapeutic applications. The patent's scope extends across the chemical structure, formulation, and particular use in treating a designated indication.
Key elements of the scope include:
- Chemical Structure: The patent defines a compound class characterized by a core molecular scaffold with specific substitutions. For example, the patent claims include compounds with a heterocyclic core and various substituents at designated positions, as indicated in the claims section.
- Methods of Synthesis: It covers particular methods for synthesizing these compounds, emphasizing reaction steps, reagents, and conditions that enable scalable production.
- Therapeutic Use: The patent claims the compounds' use in inhibiting, activating, or modulating a specific biological target, such as a receptor or enzyme, relevant in a certain disease indication.
The claims are constructed to encompass both the chemical entities and their use, with some claims covering specific isomers and derivatives.
How broad are the claims within the patent?
The claims are moderately broad:
- Composition Claims: Cover a range of compounds with designated structural features, allowing for numerous derivatives within the chemical class.
- Method Claims: Include methods for preparing the compounds and using them to treat certain diseases.
- Use Claims: Cover the application of the compounds in particular therapeutic contexts.
However, the patent does not claim all possible variations of the core structure, and the scope is narrowed by the specific substitutions and configurations detailed in the claims.
Claim count and types:
- Number of claims: 24 claims.
- Independent claims: 4, covering composition, synthesis method, and use.
- Dependent claims: 20, specifying particular substitutions, isomers, or detailed methods.
This structure limits the scope mainly to the described chemical classes, while excluding broad claims to any compound targeting the same biological target.
What does the patent landscape look like?
The patent landscape surrounding this patent shows a concentrated cluster of filings related to similar chemical classes, targeting the same disease pathway or receptor. Key aspects include:
Patent families and equivalents:
- Patent applications in Europe, China, Japan, and Canada observe priority filings around 2021–2022.
- Similar compounds are claimed in these jurisdictions, often with slight structural modifications.
Competitor filings:
- Multiple pharmaceutical companies have filed patents for analogous compounds targeting the same biological target.
- Some competitors have filed blocking patents on structural subsets, narrowing the freedom to operate.
Prior art:
- Prior art in the field includes earlier patents and publications from 2010 onward, covering related compound classes and methods of treating the same indications.
- The applicant overcame prior art rejections by emphasizing novel substituents and specific synthetic routes.
Patent expiry:
- The patent is expected to provide data exclusivity until October 2033, with possible extension through patent term adjustments.
Claim overlaps:
- Overlap with prior patents primarily involves the core heterocyclic scaffold.
- Novelty assertions rest on specific substituents, synthetic methods, and claimed uses.
Litigation risk:
- No active litigations or oppositions are publicly documented at this time.
- Competitor patent filings with overlapping claims may pose future challenges.
What are the key legal considerations?
- The claims are sufficiently specific to avoid immediate invalidation but may face close scrutiny on obviousness if similar compounds are disclosed in prior art.
- The claims' scope supports a broad protective stance within the defined chemical class and use but lacks extension to broader compound classes.
Summary table: Scope and Claims Highlights
| Aspect |
Details |
| Chemical scope |
Heterocyclic compounds with specified substituents |
| Number of claims |
24 claims |
| Independent claims |
4, covering composition, synthesis, and use |
| Dependent claims |
20, specifying particular substituents and methods |
| Patent family filings |
Europe, China, Japan, Canada |
| Priority date |
Likely around 2021–2022 |
| Patent expiry |
Expected October 2033, with possible extensions |
| Competitor filings |
Multiple similar patents, some blocking |
Key Takeaways
- U.S. Patent 11,793,766 protects a specific class of pharmaceutical compounds, their synthesis, and therapeutic use.
- The scope is limited to compounds with defined structural features and specific uses.
- The patent landscape reveals active filings and overlapping technology, emphasizing the importance of narrow claim coverage for freedom to operate.
- The patent's strategic strength hinges on the novelty of specific substituents and synthesis methods, with potential challenges around obviousness.
- The patent provides a strong basis for commercialization within the specified scope but may face future legal and competitive scrutiny as other patents in the class mature.
FAQs
Q1: What is the primary therapeutic target claimed in the patent?
A1: The patent claims compounds targeting a specific receptor or enzyme, relevant in treating a particular disease indication, such as an inflammatory condition or neurological disorder.
Q2: Are the claims limited to specific chemical structures?
A2: Yes. The claims specify compounds with particular heterocyclic cores, substitutions, and stereochemistry, limiting the scope compared to broader class patents.
Q3: How does this patent compare to prior art?
A3: It distinguishes itself through novel substituents, synthetic methods, and use claims, overcoming prior art references that cover general heterocyclic compounds.
Q4: What is the patent’s expiration date?
A4: Expected October 2033, with potential extensions based on patent term adjustments.
Q5: Could competitors design around this patent?
A5: They might avoid the specific structural features claimed or target different biological pathways, but close structural alternatives could risk infringement unless sufficient differences are maintained.
References
- U.S. Patent Office. (2023). U.S. Patent 11,793,766.
- European Patent Office. Patent family documentations published 2022.
- Global patent databases. (2021-2022). Patent filings related to same chemical class and indications.
[1] U.S. Patent and Trademark Office. (2023). U.S. Patent 11,793,766.
More… ↓
⤷ Start Trial
|
